Medication Description: Dexrazoxane (Dexrazoxane)
(+) - (S) -1,4-Propylene-2,6-piperazinedione.
Synonym: Cardioxan, Cardioxan.
White crystalline powder. Well soluble in water.
Cyclic analogue of EDTA (ethylenediaminetetraacetic acid).
Forms chelate bonds with salts of iron and copper.
Violates the formation of the doxorubicin-iron complex (and other anthracycline antibiotics with iron), and also prevents the appearance of iron-containing free radicals that mediate the cardiotoxicity of anthracycline antitumor antibiotics.
Prescribed for the prevention of cardiomyopathy with the use of anthracycline anti-tumor antibiotics.
Adults are administered intravenously at a dose of 0.5 g / m 2 (0.5 g is dissolved in 0.167 M sodium lactate solution to a concentration of 10 mg / ml or in 0.9% sodium chloride solution or 5% glucose solution to a concentration of 1.3 -5 mg / ml) 30 minutes before intravenous administration of doxorubicin at a dose of 50 mg / m 2 or (Scheme II) at a dose of 1 g / m 2 (0.5 g is dissolved in 25 ml of water for injection, then in Ringer’s lactate solution or sodium lactate to 250-500 ml) for 45-60 minutes before the administration of doxorubicin (first 20-30 minutes infusion, then 20-30 minutes break). Bred ex tempore. The solution is valid for 6 hours after preparation.
Possible side effects: dyspepsia, alopecia, leukopenia, thrombocytopenia, pain at the injection site.
The drug is contraindicated in pregnancy and lactation.
Product form: lyophilized powder for injection solutions in vials of 0.5 g, complete with solvent.
Storage: List B.